Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia

被引:7
|
作者
Song, Menghuan [1 ]
Ware, Robert S. [1 ,2 ]
Doan, Tan N. [3 ]
McPherson, Lyn [1 ,2 ]
Trollor, Julian N. [4 ]
Harley, David [1 ]
机构
[1] Univ Queensland, Mater Hosp, Queensland Ctr Intellectual & Dev Disabil, Mater Res Inst, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia
[3] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ New South Wales, Dept Dev Disabil Neuropsychiat, Fac Med, Sydney, NSW, Australia
来源
BJPSYCH OPEN | 2020年 / 6卷 / 06期
关键词
Psychotropic drugs; intellectual disability; off-label use; inappropriate prescribing; adolescent; ADULTS; DRUGS;
D O I
10.1192/bjo.2020.125
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychotropic medications are sometimes used off-label and inappropriately. This may cause harm to adolescents with intellectual disability. However, few studies have analysed off-label or inappropriate prescribing to this group. Aims To examine the appropriateness of psychotropic prescribing to adolescents with intellectual disability living in the community in south-east Queensland, Australia. Method Off-label medication use was determined based on whether the recorded medical condition treated was approved by the Australian Therapeutic Goods Administration. Clinical appropriateness of medication use was determined based on published guidelines and clinical opinion of two authors who specialise in developmental disability medicine (J.N.T. and D.H.). Results We followed 429 adolescents for a median of 4.2 years. A total of 107 participants (24.9%) were prescribed psychotropic medications on at least one occasion. Of these, 88 (82.2%) were prescribed their medication off-label or inappropriately at least once. Off-label or inappropriate use were most commonly associated with challenging behaviours. Conclusions Off-label or inappropriate use of psychotropic medications was common, especially for the management of challenging behaviours. Clinical decision-making accounts for individual patient factors and is made based on clinical experience as well as scientific evidence, whereas label indications are developed for regulatory purposes and, although appropriate at a population level, cannot encompass the foregoing considerations. Education for clinicians and other staff caring for people with intellectual disability, and a patient-centred approach to prescribing with involvement of families should encourage appropriate prescribing. The effect of the National Disability Insurance Scheme on the appropriateness of psychotropic medication prescribing should be investigated.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Medication and supplement use in older people with and without intellectual disability: An observational, cross-sectional study
    Peklar, Jure
    Kos, Mitja
    O'Dwyer, Maire
    McCarron, Mary
    McCallion, Philip
    Kenny, Rose Anne
    Henman, Martin C.
    PLOS ONE, 2017, 12 (09):
  • [42] Association Between Intellectual Disability and Hair Cortisol Concentration in Adolescents in a Brazilian Population-Based Birth Cohort
    Sanchez-Luquez, Karen Y.
    Karam, Simone de Menezes
    Barros, Aluisio J. D.
    Gonzalez, Andrea
    Murray, Joseph
    de Oliveira, Isabel O.
    Matijasevich, Alicia
    Santos, Ina S.
    Tovo-Rodrigues, Luciana
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2025, 69 (03) : 214 - 223
  • [43] Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: A cross-sectional study
    Fusar-Poli, Laura
    Brondino, Natascia
    Rocchetti, Matteo
    Petrosino, Beatrice
    Arillotta, Davide
    Damiani, Stefano
    Provenzani, Umberto
    Petrosino, Carmelo
    Aguglia, Eugenio
    Politi, Pierluigi
    PSYCHIATRY RESEARCH, 2019, 276 : 203 - 209
  • [44] PTSD, Psychotropic Medication Use, and the Risk of Dementia Among US Veterans: A Retrospective Cohort Study
    Mawanda, Francis
    Wallace, Robert B.
    McCoy, Kimberly
    Abrams, Thad E.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 (05) : 1043 - 1050
  • [45] Psychotropic medication use in parents of survivors of adolescent cancer: A register-based cohort study
    Wikman, Anna
    Hoven, Emma
    Alvariza, Anette
    Lovgren, Malin
    Kreicbergs, Ulrika
    Skoglund, Charlotte
    Fransson, Emma
    Ljungman, Gustaf
    Ljung, Rickard
    Ljungman, Lisa
    CANCER MEDICINE, 2022, 11 (22): : 4341 - 4353
  • [46] Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study
    Sheehan, Rory
    Hassiotis, Angela
    Walters, Kate
    Osborn, David
    Strydom, Andre
    Horsfall, Laura
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
  • [47] The Use of iPad and eBooks to Perform Daily Living Skills Among Adolescents With Autism Spectrum Disorder and Intellectual Disability
    Yeong, Adeline M. Y.
    Dutt, Anuradha S.
    Yong, Yvonne H. L.
    Nair, Rahul
    JOURNAL OF SPECIAL EDUCATION TECHNOLOGY, 2023, 38 (02) : 161 - 173
  • [48] Prevalence of Psychotropic Drug Use in Adults with Intellectual Disability: Positive and Negative Findings from a Large Scale Study
    Tsiouris, John A.
    Kim, Soh-Yule
    Brown, W. Ted
    Pettinger, Jill
    Cohen, Ira L.
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2013, 43 (03) : 719 - 731
  • [49] Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom
    Houghton, Richard
    Liu, Chuang
    Bolognani, Federico
    AUTISM RESEARCH, 2018, 11 (12) : 1690 - 1700
  • [50] Prevalence of Psychotropic Drug Use in Adults with Intellectual Disability: Positive and Negative Findings from a Large Scale Study
    John A. Tsiouris
    Soh-Yule Kim
    W. Ted Brown
    Jill Pettinger
    Ira L. Cohen
    Journal of Autism and Developmental Disorders, 2013, 43 : 719 - 731